Phenylephrine/ketorolac
Phenylephrine/ketorolac, sold under the brand name Omidria, is a combination drug used during cataract surgery[1] or intraocular lens replacement to prevent intraoperative miosis and to reduce postoperative pain.[2] It contains phenylephrine and ketorolac.[2]
| Combination of | |
|---|---|
| Phenylephrine | Alpha-1 adrenergic receptor agonist |
| Ketorolac | Nonsteroidal anti-inflammatory |
| Clinical data | |
| Trade names | Omidria |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Routes of administration | Ocular irrigation |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| DrugBank | |
| UNII | |
| KEGG | |
It was approved for use in the United States in May 2014,[3] and in the European Union in July 2015.[4]
References
- Lawuyi LE, Gurbaxani A (2015). "The clinical utility of new combination phenylephrine/ketorolac injection in cataract surgery". Clinical Ophthalmology. Auckland, N.Z. 9: 1249–54. doi:10.2147/OPTH.S72321. PMC 4506037. PMID 26203214.
- "Omidria- phenylephrine and ketorolac injection, solution, concentrate". DailyMed. 11 December 2017. Retrieved 17 April 2020.
- "Drug Approval Package: Omidria (phenylephrine and ketorolac) Injection NDA #205388". U.S. Food and Drug Administration (FDA). 9 December 2014. Retrieved 17 April 2020.
- "Omidria EPAR". European Medicines Agency (EMA). Retrieved 17 April 2020.
External links
- "Ketorolac mixture with phenylephrine". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.